Specialty Pharmacy

Sacituzumab govitecan-hziy is the first antibody-drug conjugates approved by the FDA specifically for relapsed or refractory metastatic triple-negative breast cancer (TNBC).

Implementation of adherence programs can be effective in improving outcomes for patients and reduce costs both at the patient and systemic level.

Using CRISPR technology, researchers conducted a study aimed at identifying genes that fuel leukemia growth, in order to find new vulnerabilities in chronic myeloid leukemia that can be targeted.

An analysis has shown that aspirin is associated not only with a significant reduction in the risk of developing several cancer types.

Cancer cells avoid an immune system attack after radiation by taking control of a cell signaling pathway that helps dying cells avoid triggering an immune response.

Patients with BRAF mutations administered treatment with encorafenib/binimetinib trended toward improved and longer responses than patients who received dabrafenib/trametinib.

In preliminary data from the trial evaluating dostarlimab, the results demonstrated that the clinical activity in patients with previously treated recurrent or advanced mismatch repair (MMR)-deficient endometrial cancer had an acceptable safety profile.

The new expanded approval was based on positive results from the phase 3 E1912 study.

Treatment of ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors has a high out-of-pocket cost for patients, with substantial variation among them, according to a study.

Purdue University researchers have created technology that uses optical imaging to better help surgeons map out tumors in the body and understand how certain diseases affect activity in the brain.

Over the past 20 years, the specialty pharmacy channel has been the fastest growing segment of pharmacy practice.

Oncology/Hematology pharmacists from Boston Medical Center discuss how COVID-19 has affected their patients.

An interview with Debra Richardson, MD, examined the phase 2 study that included niraparib with bevacizumab for patients with either a complete or partial response after upfront chemotherapy for advanced ovarian cancer.

A protein secreted by fat cells may link obesity and breast cancer, according to a newly published article inTrends in Molecular Medicine.

A new study revealed that researchers have found a genetic test that could help doctors determine which patients with multiple myeloma are at “ultra high risk” of their cancer progressing aggressively in its early stages.

The FDA has granted accelerated approval to pemigatinib (Pemazyre, Incyte Corporation) as the first treatment for adults with certain types of previously treated, advanced cholangiocarcinoma.

This approval is a part of the first Project Orbis partnership between the FDA, Health Sciences Authority, and Swissmedic.

A protein, known as FOXO1, plays a critical role in heart damage resulting from treatment with the chemotherapy drug anthracycline.

N95 respirators can be decontaminated effectively and maintain functional integrity for up to 3 uses, according to a study by the National Institutes of Health (NIH).

Pharmacists are a rich resource, not only in the management of colorectal cancer, but in every aspect of health care.

The clinical practice update incorporates emerging evidence and available guidance for patients with IBD.

Additionally, this treatment gradually reduced the need for prophylactic FVII use, suggesting an effective control of bleeding that leads to a sustained clinical benefit in patients who received the highest doses of AAV5-hFVIII-SQ.

The combination of olaparib plus bevacizumab lead to a potentially meaningful improvement in progression-free survival versus olaparib alone in women with BRCA-mutated newly diagnosed ovarian cancer.

In a new study, researchers present their findings of a signaling pathway that could be used in patients with triple-negative breast cancer (TNBC) to enhance therapies in the future.

The mitomycin gel is an alkylating drug, inhibiting the transcription of DNA into RNA and stopping protein synthesis and taking away the cancer cell’s ability to multiply.

The JAVELIN trial is a randomized, open-label, phase 3 trial comparing avelumab in combination with chemotherapy versus chemotherapy alone.

The addition of pazoparib to gemcitabine enhances anti-tumor activity, particularly for patients with platinum-resistant disease who derived the most benefit from combination therapy, even in the setting of receiving prior bevacizumab.

A new study investigated the molecular impact of the cancer-killing PARP-1 inhibitor (PARPi) binding to PARP-1 and found that the drug can be structurally modified to increase its power to kill tumor cells.